HLB announced that LSK BioPharma's Rivoceranib was approved by the FDA to conduct phase 2 open-label / multicenter clinical trials for 55 patients in 12 hospitals to evaluate the efficacy and safety of recurrens, metastatic Adenoid Cystic Carcinoma.

Chairman Jin Yang Gon said, “With no standard anti-cancer drug for adenoid cystic carcinoma, we have secured efficacy and safety through the Phase 2 trial of Rivoceranib” and explained that the commercialization through rapid examination program of an orphan drug is the next step.